Osteoporosis is recognized as a major public health problem in the USA today. Approaching the 21st century, as the """"""""baby boomers"""""""" age, the societal impact of osteoporosis will increase. Recognizing the need for a concerted effort to combat this disease, the Federal Government initiated Specialized Centers of Research (SCOR) in Osteoporosis in 1987. Our SCOR brought together a panoply of basic and clinical scientists with the common goal of achieving better understanding of the pathogenesis of osteoporosis, to allow development of innovative treatment regimens. Over the past four years, our SCOR investigators have focused particularly on the roles played by the interplay between parathyroid hormone and sex steroids in the development and treatment of osteoporosis. Our cohesive approach generated a significant amount of new data, and in 1990 allowed initiation of a new therapeutic trial funded by NIH. This current application represents a request for funds to allow these productive studies to continue. The SCOR consists of five projects, each addressing with different approaches our common theme of PTH/estrogen interactions. Project 1 is a basic study which seeks to clarify the cellular mechanisms underlying the effects of PTH and estrogen on osteoclast formation and activity. In Project 2, the ovariectomized rat model is used to gain a better understanding of the mechanisms of estrogen deficiency bone loss, and the role of PTH in its prevention and treatment. Project 3 brings a new dimension to our SCOR with studies of electromechanical forces, and in particular their interaction with the PTH/estrogen systems in the development and reversal of bone loss. Project 4 utilizes the paradigm of primary hyperparathyroidism in postmenopausal women to gain further insights into PTH/estrogen interactions on skeletal homeostasis. Project 5 is a continuation of a randomized, controlled trial of the efficacy of combined estrogen and PTH administration in the treatment of established osteoporosis. Each of these projects relies heavily on the support of four """"""""Core"""""""" units: Administration/Statistics; Biochemistry; Bone Histomorphometry; and Bone Mass Measurement.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR039191-08
Application #
2079446
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1987-09-30
Project End
1997-08-31
Budget Start
1994-09-01
Budget End
1995-08-31
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Helen Hayes Hospital
Department
Type
DUNS #
157119244
City
Menands
State
NY
Country
United States
Zip Code
12204
Ascenzi, Maria-Grazia; Liao, Vivian P; Lee, Brittany M et al. (2012) Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. J Bone Miner Res 27:702-12
Zhang, Hao; Doty, Stephen B; Hughes, Christine et al. (2007) Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. J Cell Biochem 102:1011-20
Dempster, David W; Hughes-Begos, Christine E; Plavetic-Chee, Katarina et al. (2005) Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 95:139-48
Cosman, Felicia; Nieves, Jeri; Zion, Marsha et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-75
Iida-Klein, A; Lu, S Shou; Kapadia, R et al. (2005) Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186:549-57
Kurland, Etah S; Heller, Samantha L; Diamond, Beverly et al. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15:992-7
Kim, Chi Hyun; Takai, Erica; Zhou, Hua et al. (2003) Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18:2116-25
Rubin, Mishaela R; Bilezikian, John P (2003) New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32:285-307
Zhou, H; Iida-Klein, A; Lu, S S et al. (2003) Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513-20
Dempster, David W (2003) The pathophysiology of bone loss. Clin Geriatr Med 19:259-70, v-vi

Showing the most recent 10 out of 125 publications